A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Ov⦠(NCT07357415) | Clinical Trial Compass
RecruitingPhase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
United States600 participantsStarted 2026-01-24
Plain-language summary
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Have a Body Mass Index (BMI) at screening
* ā„ 30 kilogram per square meter (kg/m2) OR
* ā„ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
* Have at least one unsuccessful attempt to lose weight by dieting
Exclusion Criteria:
* Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening
* Have a prior or planned surgical treatment for obesity
* Have type 1 diabetes or type 2 diabetes
* Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
* Have had within the past 90 days before screening:
* heart attack
* stroke
* hospitalization for unstable angina or heart failure
* Have New York Heart Association Functional Classification Class IV congestive heart failure
* Have a history of chronic or acute pancreatitis
* Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening
What they're measuring
1
Percent Change from Baseline in Body Weight
Timeframe: Baseline, Week 104
Trial details
NCT IDNCT07357415
SponsorEli Lilly and Company
Sponsor typeINDUSTRY
Study typeINTERVENTIONAL
Primary completion2028-10
Contact for this trial
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or